Analytical Data
-
Gene name
Claudin-18/CLDN18.2 Protein-VLP
- Application
-
Alternative Names
Claudin-18
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P56856
-
Expression Region
28-80aa
-
Molecular Weight
32.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Claudin-18 (CLDN18) is a tight junction protein that plays a crucial role in maintaining epithelial integrity and has been identified as a significant marker for various cancers, particularly gastric and pancreatic cancers. Its isoform CLDN18.2 has garnered attention for its potential as a therapeutic target and a biomarker for immunotherapy due to its restricted expression pattern in normal tissues and overexpression in tumor cells. In recent years, researchers have explored the possibility of developing immunotherapeutic strategies, including vaccine platforms that elicit strong immune responses against CLDN18.2. Virus-like particles (VLPs) have emerged as promising tools for this purpose, owing to their ability to effectively present antigens and stimulate robust and specific immune responses without posing any risk of infection. By engineering VLPs to display CLDN18.2, researchers aim to enhance the immunogenicity of the protein, potentially leading to novel vaccine candidates for cancer treatment. This approach not only provides a means to target tumors expressing CLDN18.2 but also holds promise for personalized medicine by tailoring therapies to individual patients' tumor profiles. The ongoing research in this area seeks to optimize the immune response against CLDN18.2, paving the way for innovative immunotherapies that could improve patient outcomes in cancers where this protein plays a critical role.
